Balyasny Asset Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Balyasny Asset Management’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-277,414	Closed	-$5.4M	–	2383
2018 Q1	$5.4M	Sell	277,414 -393,168	-59%	-$7.72M	0.02%	687
2017 Q4	$11.2M	Buy	670,582 +183,891	+38%	+$3.37M	0.03%	600
2017 Q3	$9.88M	Sell	486,691 -564,793	-54%	-$10.8M	0.04%	507
2017 Q2	$16.9M	Buy	1,051,484 +821,734	+358%	+$12.1M	0.07%	369
2017 Q1	$2.91M	Buy	+229,750	New	+$2.77M	0.01%	824
2016 Q2	–	Sell	-6,250	Closed	-$200K	–	1589
2016 Q1	$200K	Buy	+6,250	New	+$220K	﹤0.01%	1130
2014 Q1	–	Sell	-83,438	Closed	-$2.1M	–	720
2013 Q4	$2.1M	Buy	+83,438	New	+$1.86M	0.03%	400

Balyasny Asset Management's IPXL Position: Q2 2018 in Review

Balyasny Asset Management sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 277,414 shares — an estimated $5.4M sold.

Balyasny Asset Management first reported a position in IPXL in Q4 2013 and held it in 7 quarters. The position peaked at $16.9M in Q2 2017. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.

Balyasny Asset Management reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
Balyasny Asset Management sold 277,414 Impax Laboratories, Inc. shares in Q2 2018, an estimated $5.4M.
Balyasny Asset Management first reported a position in Impax Laboratories, Inc. in Q4 2013 and held it in 7 quarters.
Balyasny Asset Management's Impax Laboratories, Inc. position peaked at $16.9M in Q2 2017.
1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.

Based on Balyasny Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.